These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25746024)

  • 1. Longitudinal assessment of inflammation in recipients of continuous-flow left ventricular assist devices.
    Grosman-Rimon L; Jacobs I; Tumiati LC; McDonald MA; Bar-Ziv SP; Fuks A; Kawajiri H; Lazarte J; Ghashghai A; Shogilev DJ; Cherney DZ; Rao V
    Can J Cardiol; 2015 Mar; 31(3):348-56. PubMed ID: 25746024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of inflammation in recipients of continuous-flow left ventricular assist devices.
    Grosman-Rimon L; McDonald MA; Jacobs I; Tumiati LC; Pollock Bar-Ziv S; Shogilev DJ; Mociornita AG; Ghashghai A; Chruscinski A; Cherney DZ; Rao V
    ASAIO J; 2014; 60(6):657-63. PubMed ID: 25232767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cyclic guanosine monophosphate levels and continuous-flow left-ventricular assist devices: Implications for gastrointestinal bleeding.
    Grosman-Rimon L; Tumiati LC; Fuks A; Jacobs I; Lalonde SD; Cherney DZ; Rao V
    J Thorac Cardiovasc Surg; 2016 Jan; 151(1):219-27. PubMed ID: 26515873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients.
    Thompson LO; Skrabal CA; Loebe M; Lafuente JA; Roberts RR; Akgul A; Jones V; Bruckner BA; Thohan V; Noon GP; Youker KA
    J Surg Res; 2005 Jan; 123(1):25-32. PubMed ID: 15652947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients.
    Caruso R; Verde A; Cabiati M; Milazzo F; Boroni C; Del Ry S; Parolini M; Vittori C; Paino R; Martinelli L; Giannessi D; Frigerio M; Parodi O
    J Heart Lung Transplant; 2012 Jun; 31(6):625-33. PubMed ID: 22386451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device.
    Bruggink AH; de Jonge N; van Oosterhout MF; Van Wichen DF; de Koning E; Lahpor JR; Kemperman H; Gmelig-Meyling FH; de Weger RA
    J Heart Lung Transplant; 2006 Feb; 25(2):174-80. PubMed ID: 16446217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Type Natriuretic Peptide Levels Predict Ventricular Arrhythmia Post Left Ventricular Assist Device Implantation.
    Hellman Y; Malik AS; Lin H; Shen C; Wang IW; Wozniak TC; Hashmi ZA; Pickrell J; Jani M; Caccamo MA; Gradus-Pizlo I; Hadi A
    Artif Organs; 2015 Dec; 39(12):1051-5. PubMed ID: 25864448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure.
    Passino C; Maria Sironi A; Favilli B; Poletti R; Prontera C; Ripoli A; Lombardi M; Emdin M
    Int J Cardiol; 2005 Sep; 104(1):39-45. PubMed ID: 16137508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous-flow left ventricular assist device therapy in patients with preoperative hepatic failure: are we pushing the limits too far?
    Weymann A; Patil NP; Sabashnikov A; Mohite PN; Garcia Saez D; Bireta C; Wahlers T; Karck M; Kallenbach K; Ruhparwar A; Fatullayev J; Amrani M; De Robertis F; Bahrami T; Popov AF; Simon AR
    Artif Organs; 2015 Apr; 39(4):336-42. PubMed ID: 25345547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-type natriuretic peptide levels and continuous-flow left ventricular assist devices.
    Sareyyupoglu B; Boilson BA; Durham LA; McGregor CG; Daly RC; Redfield MM; Edwards BS; Frantz RP; Pereira NL; Park SJ
    ASAIO J; 2010; 56(6):527-31. PubMed ID: 21245799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age on outcomes following continuous-flow left ventricular assist device implantation.
    Lushaj EB; Badami A; Osaki S; Murray M; Leverson G; Lozonschi L; Akhter S; Kohmoto T
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):743-8. PubMed ID: 25770085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular reverse remodeling with a continuous flow left ventricular assist device measured by left ventricular end-diastolic dimensions and severity of mitral regurgitation.
    Morgan JA; Brewer RJ; Nemeh HW; Murthy R; Williams CT; Lanfear DE; Tita C; Paone G
    ASAIO J; 2012; 58(6):574-7. PubMed ID: 23103696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraplatelet reactive oxygen species, mitochondrial damage and platelet apoptosis augment non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist device.
    Mondal NK; Sorensen EN; Hiivala NJ; Feller ED; Pham SM; Griffith BP; Wu ZJ
    Platelets; 2015; 26(6):536-44. PubMed ID: 25167344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients.
    Grosman-Rimon L; McDonald MA; Freedman D; Yip P; Cherney DZ; Rao V
    J Card Surg; 2018 Jul; 33(7):403-411. PubMed ID: 29900585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.
    Atkins BZ; Hashmi ZA; Ganapathi AM; Harrison JK; Hughes GC; Rogers JG; Milano CA
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1247-52. PubMed ID: 23870154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation.
    Rajagopal K; Daneshmand MA; Patel CB; Ganapathi AM; Schechter MA; Rogers JG; Milano CA
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1373-9. PubMed ID: 23312101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after implantation of partial-support left ventricular assist devices in inotropic-dependent patients: Do we still need full-support assist devices?
    Sabashnikov A; Popov AF; Bowles CT; Mohite PN; Weymann A; Hards R; Hedger M; Wittwer T; Wippermann J; Wahlers T; Schoendube FA; Simon AR
    J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1115-21; discussion 1021-2. PubMed ID: 25129605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial size and fibrosis changes during left ventricular assist device support.
    Yamada Y; Saito S; Nishinaka T; Yamazaki K
    ASAIO J; 2012; 58(4):402-6. PubMed ID: 22739784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy.
    Glick A; Michowitz Y; Keren G; George J
    Isr Med Assoc J; 2006 Jun; 8(6):391-5. PubMed ID: 16833167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.